Page 70 - Drug Class Review
P. 70
Page 65 of 205
Drug Effectiveness Review Project
placebo 70.80 NR NR NR
rivastigmine 6 mg/d 68.68 NR NR NR Secondary Outcome Measures: FOME; Digit Symbol Substitution test; BVR; Trail Making test; No statistically significant differences between RIV and placebo for NOSGER Significantly more patients on RIV 6 mg/d than on placebo had marked or moderate improvements on CGIC (42.7% vs. 29.9%; P = 0.05); 4 mg/d differences not significant At week 13, patients on RIV 6 mg/d had significantly better scores on Digit Symbol Substitution test and FOME (P < 0.05) than placebo-treated patients; 4 mg/d differences not significant No statistically signi
Alzheimer classification: Mild-moderate
Groups similar at baseline: NR
rivastigmine 4 mg/d 68.62 NR NR NR Primary Outcome Measures: CGIC NOSGER; MMSE Timing of assessments: Baseline and weeks 7 and 13 Health Outcome Measures: Intermediate Outcome Measures: Making test
• • • • •
Final Report Update 1 Authors: Agid et al. Year: 1998 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Other germane population qualities: OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
